PHARMA PHARMANIAGA BERHAD
PHARMA scores 27/100 on fundamentals: in the bottom 11% of 1120 scored Bursa Malaysia stocks. Its strongest area is Risk (50/100); its weakest is Cash & Dividends (13/100). It carries 2 warning flags: Weak Spot, Recent Loss.
- Carries a Weak Spot flag
- Carries a Recent Loss flag
Nearby peers
Ranks #28 of 30 in Health Care by score
One-Minute Summary
Why PHARMA scores 27
A financially stretched stock, but cash & dividends needs attention.
After Jun '26 results: 23 → 26+3· P/E Ratio Weak → OkaySee all movers →
Business Strength
20Why 20?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 22.3% over 4 years: customers keep spending more with this company.
The company lost money in recent years: the bars below zero are losses, not profits.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales have stayed roughly flat over the last 8 quarters.
Profit fell about 87.6% over the last 8 quarters.
Financial Safety
33Why 33?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings fell about 34.5% over 4 years: the company is steadily getting safer.
Short-term assets vs bills, with Current Ratio
Cash & DividendsLowest pillar
13Why 13?
Show 3 charts
Operating vs Free Cash Flow
Cash flow has been weak or negative recently: the business is burning cash, not building it.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends were cut during this period: payouts here are not guaranteed pocket money.
Price Fairness
17Why 17?
Show chart
Score vs Share Price
The share price is down about 40.4% over the past year.
What happened, and how the price moved
- 14 Sep 2026Ex-dividend 0.48 sen a share0.4% yield at that priceWeek▼4.7%KLCI −1.3%Month▼23.8%KLCI −4.6%
- 13 Aug 2026Pharmaniaga 2Q profit jumps more than three fold on lower finance costs · The Edge Malaysia +6 moreScore 23 → 26Week0.0%KLCI −0.5%Month▼6.0%KLCI −1.6%
- 5 Jun 2026Ex-dividend 1.3 sen a share1.0% yield at that priceWeek▲6.6%KLCI +0.6%Month▼8.5%KLCI −0.9%
- 18 May 2026Pharmaniaga's recovery continues with 1Q net profit of RM31.47mil · The Star +4 moreScore 35 → 23Week0.0%KLCI −1.6%Month▲0.9%KLCI −3.3%
Risk
50Why 50?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Get an email when PHARMA's score changes, and why
Own more than one stock? Check them all at once ›Sector peers
PHARMA (7081.KL) scores 27/100 (Weak) on Score Your Stock's educational fundamentals model: in the bottom 11% of 1120 scored Bursa Malaysia stocks.
Its strongest pillar is Risk (50/100); its weakest is Cash & Dividends (13/100).
PHARMA ranks #28 of 30 scored Health Care stocks on Score Your Stock.
Yes. PHARMA (7081.KL) has a dividend yield of 1.6%, from dividends with an ex-date in the last 12 months. It pays out 39% of its profit as dividends. Its Cash & Dividends pillar scores 13/100.
Open a trading account and a CDS account with any Bursa Malaysia broker, then place a buy order for 7081.KL in lots of 100 shares. Broker fees for the same trade differ a lot between brokers: compare them for your trade size at https://scoreyourstock.com/tools/brokerage-fee-calculator.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk (for banks, Financial Safety checks impaired loans, loan loss coverage and the CET1 capital ratio instead of debt and liquidity). Full methodology, the default weights, and how to set your own: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Makes generic medicines and is the main distributor of drugs and medical supplies to Malaysian government hospitals. On Score Your Stock's fundamentals check, it scores 27/100, rated Weak. Its biggest strength is Risk (50/100); its main watch-out is Cash & Dividends (13/100). Shares currently cost about 18 years of its current profit to buy (P/E 17.7×). It also pays back about 1.6% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/klse/7081-pharma
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | RM 4.2b | RM 58.9m | RM -51.1m | RM -152.7m | RM -101.6m | RM 152.3m | RM 780.9m | RM 480.6m | RM 458.6m | RM 1.7b | RM 1.6b | RM 2.5b | RM 2.0b | RM 757.9m | - | 13% | 1% | 1.7× | 1.0× | 2.8× | 39% | - | - | - |
| 2025 | RM 3.9b | RM 48.5m | RM -17.7m | RM -56.4m | RM -38.7m | RM 258.6m | RM 819.8m | RM 690.0m | RM 434.5m | RM 1.5b | RM 1.6b | RM 2.2b | RM 1.8b | RM 729.8m | RM 0.0m | 11% | 1% | 1.9× | 0.9× | 2.2× | - | 0% | 37.4× | 4.2× |
| 2024 | RM 3.8b | RM 131.8m | RM 42.7m | RM 3.1m | RM -39.6m | RM 132.4m | RM 1.2b | RM 1.1b | RM -171.3m | RM 1.2b | RM 2.0b | RM 2.0b | RM 2.1b | RM 612.8m | RM 0.0m | -77% | 4% | -7.0× | 0.6× | 3.7× | - | 0% | 3.7× | -2.9× |
| 2023 | RM 3.4b | RM -80.2m | RM 47.0m | RM -26.7m | RM -73.7m | RM 114.7m | RM 1.2b | RM 1.0b | RM -299.1m | RM 1.1b | RM 2.0b | RM 1.9b | RM 2.2b | RM 580.6m | RM 0.0m | 27% | -2% | -4.0× | 0.6× | -0.3× | -10% | 0% | -6.8× | -1.8× |